Aurealis Therapeutics

Anteris Technologies Ltd (formerly known as Admedus (formerly known as Allied Healthcare Group Ltd), through its subsidiary Admedus Vaccines (formerly Coridon)), is a structural heart company delivering clinically superior solutions, focused on the development of next-generation technologies with world class partners.In July 2010, Australian medical devices company, Allied Medical, planned to acquire a 38.6% controlling stake in Coridon via a AUD $3 million (US $2.6 million) rights issue. Under the agreement, Allied Medical could acquire up to 55.7% interest. In June 2011 BioMD and Allied Medical Ltd were merged to form Allied Healthcare Group. In April 2012, Allied Healthcare held a 44% stake in Coridon. In July 2013, Allied Healthcare increased the stake in Coridon from 44 to 50.1%.In February 2023, Anteris Technologies Ltd completed equity fundraising, as a result of which the company issued 1.458 million new ordinary shares at an issue price of $24.00

Atb Therapeutics is a developer of monoclonal antibodies from plant cells designed to treat cancer

Aurealis Pharma, founded in April 2010 is an innovative driver of biomedical inventions from idea to non-clinical proof-of-concept. The company has focused on the development of therapeutics for immune related disorders such as chronic inflammation and cancer.In April 2016, the company changed its principal address from Finland to Hochbergerstrasse, 60CCH-4057 Basel, Switzerland.In February 2019, the company formed a spin-off, Aurealis Therapeutics as a new legal entity.In August 2017, the company closed a series A financing of 5.6 million CHF (US $5.8 million).In January 2016, the company closed a seed C financing round of 3.3 million CHF (US $3.27027).In December 2013, Aurealis closed a seed financing round and raised EUR 1.5 million (US $20.38)